China Medical GatewayLoading your healthcare gateway…

Wang Zhang Li

Wang Zhang Li — Chief Physician — Pulmonary Oncology — Tianjin Medical University Cancer Hospital

Specialties

Various complex surgeries for lung cancer and systematic lymph node dissection in lung cancer surgery; performed mediastinoscopy to improve the accuracy of lung cancer diagnosis and staging; actively promoted and proficiently carried out complete thoracoscopic lung cancer resection.

Professional Experience

Male, chief physician, professor, doctoral supervisor, national key specialty leader in thoracic surgery. He has been engaged in clinical thoracic oncology surgery, mainly focusing on early diagnosis, surgical treatment, comprehensive treatment of lung cancer, as well as basic and clinical research related to lung cancer. He conducts multiple thoracoscopic lung cancer surgery training sessions nationwide each year and organizes numerous standardized thoracoscopic lung cancer surgeries and thoracoscopic surgery demonstration live online broadcasts across more than 30 provinces and cities in China, playing an important role in advancing minimally invasive surgery for lung cancer in the country. In 2016, he introduced a new technology for minimally invasive lung cancer surgery assisted by the da Vinci surgical robot system, pioneering a new field in pulmonary tumor surgery. Since 2009, he has carried out driver gene testing for lung cancer, actively promoting individualized diagnosis and treatment at the molecular level, and was among the first to enter the era of precision therapy. He has led multiple national multicenter clinical trials, presided over many international and domestic academic conferences, and actively promoted the internationalization of clinical and translational research in lung cancer in China. Under his leadership, the department has been ranked among the top ten in the Ministry of Health's Top Ten Thoracic Surgery Departments nationwide and in China Hospital Best Specialty Reputation rankings for thoracic surgery for multiple consecutive years. He has participated in the formulation of diagnostic and treatment guidelines such as the 'CSCO Lung Cancer Guidelines,' 'Guidelines for the Diagnosis and Treatment of NSCLC with EGFR Mutation and ALK Fusion Gene Positivity,' and the 'Chinese Guidelines for the Diagnosis and Treatment of ALK-Positive Anaplastic Lymphoma Kinase (ALK) Non-Small Cell Lung Cancer.' He has published over 80 papers in important domestic and international journals, served as the chief editor of 'Lung Cancer,' and contributed to monographs including 'Surgical Oncology.' He is a member of the editorial boards of the 'Chinese Journal of Surgery' and 'Cancer.' He has undertaken numerous research projects at the national, municipal, and departmental levels.

Professional Roles

Former Chairman of the Lung Cancer Committee of the Chinese Anti-Cancer Association, Vice Chairman of the Non-Small Cell Lung Cancer Committee of CSCO, Chairman of the Lung Cancer Committee of the Tianjin Anti-Cancer Association, Director of the Tianjin Lung Cancer Diagnosis and Treatment Center, Vice Chairman of the Thoracic Surgery Society of the Tianjin Medical Association

Return to Home